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Heat shock proteins (HSPs) have been linked to the therapy of both cancer and inﬂammatory diseases, approaches that utilize
contrasting immune properties of these proteins. It would appear that HSP family members Hsp60 and Hsp70, whether
from external sources or induced locally during inﬂammation, can be processed by antigen-presenting cells and that HSP-
derived epitopes then activate regulatory T cells and suppress inﬂammatory diseases. These eﬀects also extend to the HSP-
rich environments of cancer cells where elevated HSP concentrations may participate in the immunosuppressive tumor milieu.
However, HSPs can also be important mediators of tumor immunity. Due to their molecular chaperone properties, some HSPs
can bind tumor-speciﬁc peptides and deliver them deep into the antigen-processing pathways of antigen-presenting cells (APCs).
In this context, HSP-based vaccines can activate tumor-speciﬁc immunity, trigger the proliferation and CTL capabilities of cancer-
speciﬁc CD8+ T cells, and inhibit tumor growth. Further advances in HSP-based anticancer immunotherapy appear to involve
improving the properties of the molecular chaperone vaccines by enhancing their antigen-binding properties and combating the
immunosuppressive tumor milieu to permit programming of active CTL capable of penetrating the tumor milieu and speciﬁcally
targeting tumor cells.
1.Introduction
The primary function of the immune response is to distin-
guishbetweenmolecules,usuallyproteins,thatareconstrued
as either components of self or nonself molecules likely
derived from invading organisms. Through the mechanisms
of central and peripheral tolerance, the immune response
is deterred from attacking cells recognized as self [1, 2].
The case of tumor immunity is however more ambiguous.
Tumor cells arise from normal cells that the immune cells
are educated to tolerate. However, it has been shown that
tumors can express speciﬁc antigens not displayed by the
corresponding normal tissues and that these epitopes can be
recognized by CD8+ T lymphocytes [3, 4]. These polypep-
tides may be derived from embryonic antigens reawakened
during malignant progression or from mutated proteins that
arise due to development of a mutator phenotype and loss
of DNA repair mechanisms that characterize tumorigenesis.
Despite the potential for speciﬁc immunity and the existence
of tumor antigens, it is evident that cancers arise, grow,
progress, and lead to the death of greater than 30% of
the human population. A depressing variety of mechanisms
have been found which may account for the ability of
tumors to dismiss the attentions of the immune response.
These include a “loss-of-self” mechanism in which major
histocompatibility class I antigens cease to be expressed on
the tumor cell surface, thus masking the presence of the
tumor proteome and evading CD8+ killing [5]. Additional
mechanisms include the expression by cancer cells of Fas
ligand that can recognize the presence of proapoptotic Fas
on the tumor cell surface and trigger programmed cell death
of CTL [6]. In addition, the nonmalignant cell populations
that migrate into the tumor microenvironment appear to
play a key role in deterring immunity [7–10]( Figure 1).
It is known that although cytotoxic CD8+ cells progress
to and arrest at the periphery of many tumors, crossing
the tumor capillary wall comprises a barrier to entry of
such cells; indeed, ability of CTL to penetrate tumors
is a favorable prognostic feature [11–13]. As mentioned,
however, tumors also attract a range of normal cells in2 Autoimmune Diseases
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Figure 1: The cell biology of the tumor milieu: the role of heat shock proteins. The upper part of the ﬁgure depicts tumor cells (pale blue),
including cancer cells with a cuboid epithelial shape and more spindle-shaped cancer stem cells (CSCs), suggesting the EMT (epithelial-
mesenchymal transition) characteristics ascribed to CSC. The tumor is represented as a heterogeneous cell colony containing myeloid
suppressor cells (MDSCs; green), Treg (dark blue), and tumor-associated ﬁbroblast (TAF; orange). Dominant cytokines in the tumor
microenvironment include IL-10 and TGFβ. The growth factors FGF and VEGF are secreted by TAF. To the left of the ﬁgure is depicted a
tumor capillary containing CD4+ T cells (red) that have stalled at the capillary wall. Tumor cells are depicted as secreting Hsp70-containing
exosomes (black circles) that recruit MDSCs as well as free Hsp70 that may also trigger immunosuppressive responses. The lower section
suggests the potential eﬀects of therapy using molecular chaperone vaccines, in which IL-6 is now at high levels and the cytokine proﬁle is
proinﬂammatory,cognateCTLhascrossedthecapillarywall,penetratedthetumorinterstitialspaces,andrecognizedMHCclassIassociated
with tumor antigens. Such tumor cells can then be killed in an antigen-speciﬁc manner. In addition, Hsp70-peptide complexes (Hsp70.PC)
are secreted from necrotic tumor cells and can trigger anticancer CTL after entering APC and cross-presentation to CD4+ T cells in aﬀerent
lymph nodes.
a process that resembles a normal wound-healing response.
Invading cells include regulatory T lymphocytes (Treg),
primary players in peripheral tolerance and in the defense
against autoimmunity [14, 15]. Treg can be distinguished
by a surface phenotype of CD4+CD25+, as well as the
expression of the forkhead box transcription factor Foxp3
that regulates many Treg functions. Treg exhibit multiple
immunosuppressive mechanisms including the secretion of
cytokines such as transforming growth factor beta (TGFβ)
andinterleukin-10(IL-10),thekillingofCTL,andinhibition
of immune cells through a cell contact mechanism [15].
Treg are known to congregate in tumors and may thus
mediate immunosuppression [14]. It may be signiﬁcant that
cancer stem cells (CSCs) that account for tumor initiation,
metastasis, and resistance to many forms of therapy can
attractTregandleadtotheexpressionofimmunosuppressive
IL-10[16,17].Anotherclassofimmunoregulatorycellsasso-
ciatedwithtumorsincludesmyeloid-derivedsuppressorcells
(MDSCs). MDSCs are a heterogeneous population of early
myeloid precursors, immature granulocytes, macrophages,
and DC that can suppress CD4+ and CD8+ T cells, NK and
NKT cells and promote development of Treg by multiple
mechanisms [10]. In addition, many tumors contain tumor-
associated macrophages (TAMs) that are also suppressors of
tumor immunity through production of IL-10, stimulation
of Treg, and synthesis of the coinhibitory factor CTLA-4
[9]. Also attracted to the tumor are mesenchymal stem cells
(MSCs) that can give rise to a tumor-associated ﬁbroblast
(TAF) population that supplies growth factors such as FGF,
TGFβ, and VEGF required for growth and angiogenesis
(Figure 1). The tumor milieu can contain a small fraction of
cells of mesenchymal origin identiﬁed by surface ﬁbroblast
activation protein-a (FAP cells) that suppress antitumor
immune responses [18].
2. Immune Properties of Heat Shock Proteins
Heat shock proteins (HSPs) are stress proteins whose
synthesis is triggered by proteotoxic stresses such as heat
shock [19, 20]. The dominant functions of the HSPs are
the holding and folding of other intracellular proteins
[21]. The HSPs are thus classiﬁed among the molecular
chaperones, a group of polypeptides that mediate intra-
cellular protein quality control under both housekeeping
and stressed situations. As HSPs are often required to
interact with “client” proteins in a stoichiometric rather
than catalytic manner (holding), they are synthesized inAutoimmune Diseases 3
high intracellular concentrations, particularly during stress
[21, 22]. Thus, HSPs are induced in prodigious quantities,
and their expression dominates ongoing transcription and
translation in heat-shocked cells [23]. Early studies showed
that some bacterial HSPs of the Hsp60 and Hsp70 families,
due in part to their high concentrations, were dominant
antigens in the host responses to pathogens [24]. It was
therefore widely expected that human host HSP paralogs
might in turn promote autoimmunity by a peptidomimetic
mechanism due to the close similarity between domains in
the HSP paralogs in humans and bacteria [25]. Structural
domains conserved between the well-conserved pathogenic
and host HSPs were thus thought to be a potential source for
autoimmune/inﬂammatory diseases. However, it has turned
out that when the host Hsp60 or Hsp70 is elevated in cells, as
might be observed during inﬂammation or immunotherapy
using puriﬁed HSPs, they can be processed by professional
or nonprofessional antigen-presenting cells and thus trigger
Treg cells, mediate immunosuppression, and ameliorate
the inﬂammatory eﬀects of pathogenic proteins [26, 27].
Thus, HSPs from intracellular or extracellular sources, after
processing in cells and presentation to T lymphocytes, tend
to be immunomodulatory and can ameliorate symptoms of
inﬂammatory diseases (Figure 2). It is now well established
that HSP levels become ampliﬁed in a broad spectrum of
cancers, are required for tumor progression, and are targets
for cancer therapy [28, 29]. Increases in tumor HSP levels
have been ascribed to either the high concentrations of
mutated and misfolded oncoproteins that drive oncogenesis
or to induction of the heat shock proteins by corruption
of the signaling pathways leading to HSP expression during
malignancy [30, 31]. The elevated cohort of HSPs may thus
berequiredtochaperonetheabundantanddenaturedtumor
proteins or processed peptides derived from such proteins
and as such oﬀers a target for therapy. For immunologists,
inspection of such a situation in the cancer cell might
suggest an opportunity for immune attack on the tumor
cells [32]. Hsp70 has been observed in the extracellular
milieu and has been detected in plasma from mice and
humans [33]. In addition, the chaperone is released from
necrotic cells with compromised plasma membranes as well
as from intact unstressed cells under basal conditions, using
a deﬁned secretion mechanism [34, 35]. The situation in
tumors, with cells rich in HSP expression some of which
exist in a highly stressed microenvironment, therefore might
suggest that HSP polypeptides could be released either from
disintegrating cells in areas of necrosis or in the normal
metabolism of viable cells. However, in vivo studies showed
thatdepletionofintracellularHsp70enhancestumorgrowth
due in part to a decrease in immune killing in the tumor
[36]. These eﬀects of Hsp70 secretion were ascribed to
the fact that Hsp70 can be released from the tumor cells
packaged in exosomes, lipid-bounded particles that can
attract immunosuppressive myeloid-derived suppressor cells
(MDSCs) [36]( Figure 1). These cells have been found in the
tumor milieu and mediate immunosuppression by secreting
immunosuppressive interleukin-10, decreasing CD4+ and
CD8+ T-cell viability, and attracting Treg [10]. In this
context, extracellular HSPs can be seen to be contributing to
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Figure 2: Contrasting immunological inﬂuences of HSPs under
diﬀering contexts. We show that HSPs in cancer cells can inhibit
or promote tumor immunity, depending on the tissue context.
Tumor HSP levels become elevated during progression (blue line).
This can lead to immune-suppressive eﬀects of intracellular Hsp60
and Hsp70 as well as Hsp27, Hsp60, and Hsp70 secreted from
tumor cells. However, if tumor cells are engineered to overexpress
secretable forms of Grp78 or Gsp170 (purple line), antitumor
immune response can be generated that are at least partially due
to release of HSP tumor antigen complexes. In addition, necrotic
killing of cells along with forced expression of Hsp70 (orange line)
can lead to an inﬂammatory environment that triggers a tumor
antigen-speciﬁc immune response.
the immunosuppressive microenvironment associated with
many tumors, which are often enriched in Treg, MDSC,
and TAM, as well as tumor-associated ﬁbroblast that can
secrete TGFβ (Figure 1). The role of Hsp70 released in free
form from tumor cells as opposed to exosomal Hsp70 is
less clear. It is however known that the major inducible
Hsp70 member, hsp70.1/hspA1A, can induce the formation
ofimmaturetolerogenicDCanddecreaseT-cellproliferation
[37]. Thus, Hsp70 epitopes expressed on either tolerogenic
DC or tumor cells themselves may lead to an immune-
suppressed environment due to interaction with Treg and
suppression of CTL by multiple mechanisms [27]. In addi-
tion, the tumor cells are particularly enriched in the small
HSP Hsp27 (hspB1 gene product) [29, 31]. Extracellular
Hsp27 is frankly immunosuppressive due to inhibition of
DC diﬀerentiation and production of inhibitory mediators
thrombospondin-1 and IL-10 [38, 39]. Likewise with Hsp60,
an HSP is known to be secreted from cells [40]. When
released into the extracellular milieu, Hsp60 increases levels
of CD4+CD25+Foxp3 cells and suppresses CTL [41, 42].
Few studies have addressed the role of humoral immu-
nity in the responses of tumor cells to HSP. However,
Hsp70/MAGE-3 fusion vaccines were shown to enhance
both cellular and humoral immunity to MAGE-3 express-
ing melanoma, and B- and plasma-cell inﬁltration was
a strong prognostic factor in the response [43]. Likewise
in human esophageal cancer, simultaneous occurrence of
Hsp70 expression and B- and plasma-cell inﬁltration into
tumors was an indicator of good prognosis, even exceeding4 Autoimmune Diseases
the beneﬁts of tumor inﬁltration of CD4+ and CD8+ T
cells [44]. It is not clear how HSPs might inﬂuence cells
of the humoral response. However, Hsp60 has been shown
to interact with B cells through a pathway involving TLR
signaling and can activate na¨ ıve cells, upregulate expression
of MHC class II, and protect the cells from apoptosis [45,
46]. The latter eﬀects are accompanied by release of IL-
10 suggesting that eﬀects of extracellular Hsp60 on B cells
might provoke an immunoregulatory response. Thus, eﬀects
of extracellular HSPs on cells of the humoral response in the
tumor milieu likely involve a balancing act between potential
immunostimulatory and immunosuppressive responses.
Evidence to suggest that HSPs secreted from tumor
cells can also be immunostimulatory and lead to antitumor
immunity comes from immunotherapy studies carried out
with HSPs such as Gp96 and Grp170 engineered for
spontaneous secretion [47–50]( Figure 2). In this context,
Gp96 and Grp170 appear to trigger tumor immunity due
to their ability to chaperone intracellular tumor antigens,
enter the canonical protein secretion pathway, be taken up
byAPC,andtriggeraCTLresponsetargetingthecancercells.
SecretedextracellularHSPsreleasedfrommalignantcellscan
thuseitherfunctionaspartoftheimmunosuppressivetumor
milieu or can enhance tumor immunity by exporting tumor-
associated antigens and triggering a CTL response directed
at the tumor (Figure 2). Factors inﬂuencing the activating
or immunosuppressive eﬀects of extracellular HSPs may
include the molecular nature of the HSP (Hsp70, Gp96,
Hsp90, Hsp110, or Grp170), whether HSPs are released in
soluble form bound to antigenic polypeptides or secreted in
exosomes, as well as the relative rate of secretion of the HSP.
3.MolecularChaperone-Based
Anticancer Vaccines
Despite the evidence that Hsp60 and Hsp70 can be immuno-
suppressive and downregulate inﬂammatory autoimmune
diseases, it seems that HSPs can be used as vaccines to induce
antitumor immunity under the appropriate conditions [32,
51]. It was proposed that members of the HSP family such as
Hsp70 and gp96 could form the basis of anticancer vaccines
due to their assumed ability to bind a sample of the antigenic
polypeptides in tumor cells, as mentioned above. Indeed,
it was shown that when cells are lysed under controlled
conditions, HSP-antigen complexes can be isolated, used
as vaccines, and thus induce immunity to cancer [32, 52–
57]. This eﬀect was achieved by utilizing the biochemical
properties of Hsp70 and Hsp90 family members. In the case
of Hsp70, binding to ATP causes loss of aﬃnity for the client
polypeptide,whilebindingtoADPstabilizespeptidebinding
[22, 58]. HSP polypeptide complexes (HSP-PCs) prepared
in this way were shown to induce antigen-speciﬁc tumor
immunity [59]. For instance, Hsp70 peptide complexes
prepared using ADP aﬃnity chromatography retain peptide
clients and induce tumor immunity while use of ATP-
agarose, although permitting isolation of Hsp70 leads to a
preparation devoid of ability to induce anticancer immunity
[59]. HSP-based vaccines have been prepared using these
general principles from Hsp70, Gp96, Hsp90, Hsp110, and
Grp170 and shown to be eﬀective in deterring tumor growth
[55]. The methods permit either isolating HSPs coupled to
the (largely uncharacterized) tumor antigen repertoire to
give a personalized, polyvalent vaccine, or loading one of the
small minority of known tumor antigens to produce a highly
concentrated vaccine based on one known antigenic protein
[51]( Figure 2). Clinical trials to test the eﬃcaciousness of
this approach are underway (reviewed recently, [51]).
Immunoregulatory responses may accompany or follow
thetriggeringoftumorimmunitybyHSPantigencomplexes.
For instance, in the case of Gp96, lower concentrations
of the chaperone-antigen complex lead to immunity, while
higher doses cause immune suppression [52, 60]. These
ﬁndings might be explained by more recent studies using
a GP96-HPV vaccine which showed that lower doses of
the preparation lead to activation of CD8+ T lymphocytes,
while higher concentrations cause strong induction of
CD4+CD25+Foxp3 Treg [11]. At least in the case of Gp96,
successful vaccination appears to involve a balancing act
between immune stimulation and regulation, with the aims
of enhancing the immunotherapy arm. It is not known if
the use of other chaperones invokes the same dilemma.
However, both Hsp60 and Hsp70 have been shown to
produce immunomodulatory eﬀects and stimulate anti-
inﬂammatory Treg when used to treat inﬂammatory diseases
such as arthritis [61]. Preparation of tumor vaccines so as
to stabilize antigen binding may bias the response towards
tumor antigen-speciﬁc immunity, and use of the chaperone
complexes at relatively low concentrations may minimize the
immunomodulatory eﬀects of anticancer vaccines and favor
antitumor immunity (Figure 2).
The responses elicited in diﬀerent immune cells by
chaperone vaccines may also depend on the mechanisms
by which they interact with the surface of target cells and
are taken up into these cells. HSP peptide complexes (HSP-
PCs) have been proposed to induce antitumor immunity by
stimulating both antigen cross-presentation and by trigger-
ing innate immunity [62–65]. Although some investigators
have suggested that HSPs can be taken up by nonreceptor
route, the majority of studies suggest a receptor-mediated
mechanism [62, 66–68] .Ac o n s i d e r a b l ea m o u n to fe ﬀect has
beenexpendedonstudyinghowHSP-PCscantriggerantigen
cross-presentation in dendritic cells (DCs) [69]. Search for
receptors that might mediate this process has not revealed
a dedicated HSP receptor. Instead, HSP uptake appears to
involve scavenger receptors including LOX-1, SRECI, and
CD91 with a broad speciﬁcity as regards ligand binding
[67, 70]. There is still some controversy concerning the
relative role of the individual HSP receptors, although the
absence of CD91 from the DC surface casts some doubt
on its signiﬁcance at least in DC [62]. Both LOX-1 and
SRECI have been shown to bind avidly to Hsp70 and Hsp90
in DC and mediate antigen cross-presentation [62, 64, 71].
Indeed, non-APC such as Chinese Hamster Ovary cells can
be endowed with cross-presenting properties when stably
expressing SRECI [64]. Hsp90 can be endocytosed by scav-
enger receptors (SRs) into endosomes and transported all
the way to intracellular proteasome—the site of processingAutoimmune Diseases 5
of internalized antigens [64, 72, 73]. Hsp90 appears to assist
in transporting the antigens complexed to it across the
endosomal membrane and insertion into the proteasome.
Thus, molecular chaperones appear to be able to penetrate
deeply into the intracellular antigen processing pathways
in DC and may in this way trigger cross-presentation of
associated antigens to CD8+ and trigger CTL [72, 73]. Some
doubt exists as to the peptide-binding capacity and role
in antigen cross-presentation of the ER chaperone Gp96
[65, 74]. However, there is strong evidence for a role for
the capacity of other chaperones such as Hsp90 to bind
and mediate cross-presentation of antigenic peptides by DC
[51, 64, 69].
In addition to activating cross-presentation to CD8+
cells, HSPs may be able to interact with other immune
cells. For instance, Hsp70 can activate the class II pathway
in DC leading to CD4+ cell activation [71]. Extracellular
antigens are usually sorted and distributed between the class
I and class II pathways in DC, for presentation to CD4+
and CD8+ T lymphocytes by a number of mechanisms
(reviewed in [69]). However, this mechanism may not apply
to HSP-chaperoned antigens and, for instance, SRECI may
be able to permit Hsp90-bound chaperones to enter both the
class I and class II pathways (Murshid and Calderwood, in
preparation). For DC to interact productively with CD8+ T
cells, a second signal, in addition to activation of the T-cell
receptor, is required [75]. Such a signal could be provided by
the CD40 receptor on the surface of DC cells that can bind to
the CD154/CD40-L counterreceptors on the CD4+ surface.
Indeed for strong activation of DC and activation of na¨ ıve T
cells,individualDCinteractswiththeT-cellreceptorsofboth
CD4+ cells and CD8+ T through surface MHC class II and
class I. Interaction with the CD4+ cell “licenses” the DC for
fullCTLprogramming,permittingsurvivalandproliferation
[75, 76]. Licensing includes a range of alterations, not all of
them understood but involving the induced expression of
costimulatory molecules such as CD80/B7.1 and CD86/B7.2
that bind to counterreceptors such as CD28 constitutively
expressed on the CD8+ cell surface and, in concert with T-
cell receptor ligation, trigger a productive interaction [77].
The HSP scavenger receptor system may permit presentation
of antigens to—and activation of both CD4+ and CD8+ T
cells—DClicensingandafullyactivatedCD8+Tcellcapable
of killing tumor cell targets.
In the immune response to pathogens, a similar activa-
tion of DC can be produced by the innate immune response.
In this case, an abundant class of pathogen-associated
molecular patterns (PAMPs), designated as “danger signals,”
are released from microorganisms and can interact with
receptors on APC designated as pattern recognition receptors
(PRRs). The PAMPs trigger powerful signal transduction
responses that emanate from PRR such as Toll-like receptors
(TLRs) and result in triggering transcription of cytokines
such as tumor necrosis factor alpha (TNFa), interleukin-6,
and interleukin-12 as well as costimulatory molecules such
as CD28 [78, 79]. This second signal resembles the stimulus
provided by the licensing eﬀects of CD4+ cells discussed
above and permits CD8+ cell programming and lysis of
speciﬁc cell targets. It was suggested that in stressed tissues,
endogenous danger signals might be released from cells and
trigger eﬀects similar to the innate response to PAMPs. Such
compounds may underlie the enhanced immunogenicity
of cells that die from necrosis, rather than apoptosis:
necrotic cells would be expected to release their contents,
including endogenous danger signals rather than the cryptic
pathways of apoptotic death in which cell contents are
retained until engulfment by scavengers [80]. A number of
compounds released from stressed or dying, notably uric
acid crystals appear to ﬁt the billing of endogenous danger
signals or DAMPs and lead to sterile inﬂammation [81].
A large number of studies have suggested that Hsp70 in
particular can stimulate the PRR Toll-like receptor 4 (TLR4)
in vivo [82]. This receptor was characterized as the PRR for
lipopolysaccharides(LPSs),PAMPsderivedfromthecellcoat
of Gram-negative bacteria. LPSs from a range of organisms,
but most commonly E. coli, are endemic on the surfaces of
laboratoryglassware,contaminatemanylaboratoryreagents,
and associate avidly with HSPs [83]. This property made
some of the earlier studies using recombinant Hsp60 and
Hsp70 in in vitro studies of HSP-TLR interactions somewhat
controversial [84, 85]. However, in vivo studies show almost
overwhelming evidence of a role for Hsp70 and other HSPs
in triggering TLR4 (recently reviewed in [86]). In terms
of the responses of tumor-bearing animals to HSP-based
vaccines, TLR signaling appears to be essential. An Hsp70
vaccine derived from MC38 cells expressing the tumor
antigen MUC1 was shown to trigger DC maturation and
expression of costimulatory molecules and trigger CTL that
could kill target tumor cells in an antigen- (MUC1-) speciﬁc
manner [87]. These eﬀects were abrogated in mice bearing
mutations that lead to inhibition of TLR signaling. For
instance, in mice deﬁcient in the signaling intermediate
Myd88, an adaptor molecule downstream of TLR4 that is
essential for activation of proinﬂammatory NFκB signaling
and innate immune transcription, ability of the Hsp70
vaccine to trigger T-cell activation, and CTL activity was
reduced [87]. Knockout of TLR2 and TLR4 almost com-
pletely abrogated the ability of the vaccine to activate either
CD4+ or CD8+ cells and prevented induction of CTL [71].
Free Hsp70 may also induce other components of innate
immunity. For instance, natural killer (NK) cells can be
activated by ex vivo treatment with Hsp70 [88]. In addition,
NK cells appear to target a population of tumor cells that
express Hsp70 on the cell surface, and exteriorized Hsp70
appears to act as a receptor for killing by NK in tumor
cells [88, 89]. NK cells may also form part of the tumor
response to chaperone-based vaccines. For instance, in mice
responding to an Hsp70-Mage3 fusion vaccine, NK cells as
well as CD4+ and CD8+ T cells were required for antitumor
activity [90].
4. Autoimmunity,HeatShock Proteins,and
Cancer Therapy
Much available evidence, particularly from study of autoim-
mune responses, suggests that some HSPs play an anti-
inﬂammatory, immunosuppressive role in vivo and could6 Autoimmune Diseases
contribute to the immunoregulatory properties of the tumor
milieu by, among other eﬀects, recruiting MDSC and Treg
[27]. However, these immunosuppressive properties may be
reversed under certain circumstances, and an Hsp70-based
vaccine prepared from a fusion of tumor cells and DC
(Hsp70.PC-F)isabletooverturntolerancetotumorantigens
in vivo and mediate CTL killing of tumor cells [87, 91, 92].
In these studies, Hsp70 was prepared in a complex with
Hsp90 and a broad repertoire of tumor-associated antigens.
Another approach has attempted to recruit autoimmunity in
the cause of tumor immunotherapy. Initially it was shown
that if proliferating melanocytes were subjected to necrotic
killing in the presence of elevated levels of intracellular
Hsp70, an immune response could be generated capable
of killing distantly located, transplanted B16 melanoma
cells [93]. The rationale behind the treatment was that
melanoma cells can reexpress antigens that are also present
in proliferating melanocytes and that necrotic killing should
in principle be proinﬂammatory [80]. A broad consensus
agrees that while necrotic death is immunostimulatory,
engulfment of apoptotic cells is suppressive to the immune
response [80]. The role of Hsp70 in this system was not
fully deﬁned although it could involve chaperoning tumor
antigens for delivery to APC and immunostimulation as
shown previously [62]. In an inﬂammatory environment,
Hsp70 peptide complexes can reverse the tolerance that
develops to tumor antigens and trigger a CTL response that
inhibits tumor growth as shown previously [87]. Another
feature of this approach is that an autoimmune response,
targeting melanocytes although predicted, was not in fact
observed, a feature that was ascribed to a delayed Treg
responsetriggeredbythetherapythatpresumablydampened
autoimmunity [93]. Some of the molecular determinants
that may underlie these eﬀects were discovered in a subse-
quent study. In a similar approach, normal prostatic tissue
was destroyed by viral lysis, and this led to regression of
distant transplanted prostate cancer. These eﬀects required a
combination of necrotic killing of and Hsp70 overexpression
in the normal prostate tissue. In the absence of Hsp70,
necrotic killing led to induction of the cytokines TGFβ and
IL-10 and a Treg response. When cell killing occurred in
Hsp70 overexpressing cells, IL-6 was expressed to high level
and the combination of IL-6 and TGFβ led to the synthesis
of IL-17 [94]. IL-17 is a powerful inﬂammatory cytokine and
is involved in the conversion of CD45+Cd25+Foxp3 Treg
cells to inﬂammatory, ROR, gamma-expressing Th17 cells
that are known to play a profound role in the inﬂammatory
response[95].Thus,thecytokinemilieuintissuesexposedto
elevated HSP concentrations may be critical in determining
the direction of the response (Figures 1 and 2).
5. Discussion
As tumors progress, they develop distinct characteristics due
in part to the recruitment of nonmalignant cells to the
growing mass (Figure 1). The malignant lesions appear to
share some of the characteristics of healing wounds and are
known to attract MSC from bone marrow that can develop
into TAF and secrete cytokines that permit tumor growth
and angiogenesis [96]. In addition, tumor cells rapidly
outgrow the local microcirculation and become deﬁcient
in nutrient and oxygen supplies leading to necrosis and
attraction of tumor-associated macrophages [9]. However,
despite these vestiges of inﬂammation, the tumor milieu
tends to be immunosuppressive and is often rich in MDSC
and TAM that secrete IL-10 and chemokines [10]. The
cytokine milieu, although supporting tumor growth, is thus
rich in TGFβ and IL-10, conditions that favor development
of Treg. In addition, cancer stem cells are known to attract
Treg and be resistant to immunotherapy [17, 97]( Figure 1).
The tumor microcirculation also appears to be resistant to
penetration by CD8+ T cells [12–14]. The cell biology of
the tumor microenvironment thus seems to be an important
component in permitting tumor cells to evade immunity,
and these properties appear to reﬂect the cytokine makeup
that develops in the tumor interstitium (Figure 2). HSPs may
play a number of roles in this process as Hsp70-containing
exosomes released from tumor cells can attract MDSC
and suppress CTL-mediated immune killing. In addition,
release from cells of free Hsp27, Hsp60, and Hsp70 may
be immunosuppressive [36–38]. However, use of chaperone-
based vaccines in experimental animals can lead to the
“Holy Grail” of antigen-speciﬁc antitumor immunity and
can overturn tolerance to tumor antigens such as MUC1
[51]. These promising ﬁndings have not yet translated into
clinical advances, and results of clinical trials with HSP
vaccines have so far been modest [98]. Improvements in
responses to chaperone vaccines could come from increasing
theinﬂammatorynatureofthetumormilieubycombination
with other modalities. Conditions that increase the levels
or activity of IL-6 can increase uptake of CTL into tumors
and lead to conversion of regulatory Treg into inﬂammatory
Th17 cells [94, 99, 100]. Combination of chaperone vaccines
with ionizing radiation or focused ultrasound could be
envisaged [101, 102]. It has also been shown recently that
tumors are enriched in coinhibitory molecules that can
suppress the proliferation and viability of the CTL that
may penetrate tumors even though their T-cell receptors
may be engaged with cognate MHCI-antigen complexes on
tumors. Indeed, although CTL triggered by activated DC
in the lymph node may express costimulatory CD-28 and
are primed for immune killing, inﬂuence of the tumor
microenvironment may switch expression to high-aﬃnity
coinhibitors such as CTLA-4 or PD-1 that suppress the
signalsgeneratedbytheT-cellreceptor[103–105].Currently,
monoclonal antibodies with the properties of blocking the
eﬀects of CTLA-4 and PD-1 are being used clinically to boost
antitumorimmunityandcouldpotentiallybeusedincombi-
nation with chaperone-based vaccines [103, 104]. This may
come at considerable costs to the health of patients bearing
in mind the severe side eﬀects of preventing coinhibition in
terms of autoimmunity. Another addition to treatment that
could be contemplated might be adding an innate immune
stimulus to boost costimulation and levels of inﬂammatory
cytokines. Although original studies suggested that HSPs
might be potent activators of TLR signaling, it remains to be
shownthatHSPvaccinesactivateinnateimmunityintumorsAutoimmune Diseases 7
in vivo. Combination with virally derived oligonucleotides
containing CpG motifs (TLR9 agonists) might be suggested
[106]. Such agents are known to activate innate immunity in
DC and are being tested clinically in cancer treatment [106].
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